Genelux Common Stock Performance
| GNLX Stock | 2.69 0.20 8.03% |
On a scale of 0 to 100, Genelux Common holds a performance score of 7. The company retains a Market Volatility (i.e., Beta) of 0.59, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Genelux Common's returns are expected to increase less than the market. However, during the bear market, the loss of holding Genelux Common is expected to be smaller as well. Please check Genelux Common's maximum drawdown, as well as the relationship between the skewness and day typical price , to make a quick decision on whether Genelux Common's current trending patterns will revert.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Genelux Common are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak essential indicators, Genelux Common showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 8.03 | Five Day Return 6.32 | Year To Date Return (81.89) | Ten Year Return (56.26) | All Time Return (56.26) |
1 | Disposition of 23383 shares by Szalay Aladar of Genelux Common at 2.7028 subject to Rule 16b-3 | 09/09/2024 |
2 | Disposition of 20384 shares by Szalay Aladar of Genelux Common at 2.5109 subject to Rule 16b-3 | 09/10/2024 |
3 | Disposition of 31376 shares by Szalay Aladar of Genelux Common at 2.6207 subject to Rule 16b-3 | 09/11/2024 |
4 | Disposition of 31777 shares by Szalay Aladar of Genelux Common at 2.7294 subject to Rule 16b-3 | 09/12/2024 |
5 | Disposition of 33080 shares by Szalay Aladar of Genelux Common at 2.5679 subject to Rule 16b-3 | 09/13/2024 |
6 | Acquisition by Joseph Cappello of 11557 shares of Genelux Common subject to Rule 16b-3 | 09/24/2024 |
7 | Disposition of 5200 shares by Yong Yu of Genelux Common at 19.106 subject to Rule 16b-3 | 10/01/2024 |
8 | Acquisition by Thomas John of 2500 shares of Genelux Common at 5.25 subject to Rule 16b-3 | 10/02/2024 |
9 | Acquisition by Scigalla Paul of 16666 shares of Genelux Common at 6.0 subject to Rule 16b-3 | 10/18/2024 |
10 | Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer | 10/22/2024 |
11 | While institutions invested in Genelux Corporation benefited from last weeks 34 percent gain, individual investors stood to gain the most | 10/31/2024 |
12 | Genelux GAAP EPS of -0.19 beats by 0.01 | 11/15/2024 |
13 | Frazier Life Sciences Appoints John Smither and Jim Williams as Senior Advisors | 11/19/2024 |
| Begin Period Cash Flow | 397 K |
Genelux |
Genelux Common Relative Risk vs. Return Landscape
If you would invest 208.00 in Genelux Common on August 31, 2024 and sell it today you would earn a total of 61.00 from holding Genelux Common or generate 29.33% return on investment over 90 days. Genelux Common is currently generating 0.6228% in daily expected returns and assumes 6.6649% risk (volatility on return distribution) over the 90 days horizon. In different words, 59% of stocks are less volatile than Genelux, and 88% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Genelux Common Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Genelux Common's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Genelux Common, and traders can use it to determine the average amount a Genelux Common's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0934
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | GNLX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.66 actual daily | 59 59% of assets are less volatile |
Expected Return
| 0.62 actual daily | 12 88% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 7 93% of assets perform better |
Based on monthly moving average Genelux Common is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Genelux Common by adding it to a well-diversified portfolio.
Genelux Common Fundamentals Growth
Genelux Stock prices reflect investors' perceptions of the future prospects and financial health of Genelux Common, and Genelux Common fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Genelux Stock performance.
| Return On Equity | -0.89 | ||||
| Return On Asset | -0.45 | ||||
| Current Valuation | 60.89 M | ||||
| Shares Outstanding | 34.54 M | ||||
| Price To Book | 2.81 X | ||||
| Price To Sales | 11,613 X | ||||
| Revenue | 170 K | ||||
| Gross Profit | 11.07 M | ||||
| EBITDA | (26.46 M) | ||||
| Net Income | (28.3 M) | ||||
| Total Debt | 2.52 M | ||||
| Book Value Per Share | 0.74 X | ||||
| Cash Flow From Operations | (20.27 M) | ||||
| Earnings Per Share | (0.94) X | ||||
| Market Capitalization | 92.91 M | ||||
| Total Asset | 27.89 M | ||||
| Retained Earnings | (221.52 M) | ||||
| Working Capital | 17.65 M | ||||
About Genelux Common Performance
Evaluating Genelux Common's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Genelux Common has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Genelux Common has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.01) | (1.07) | |
| Return On Capital Employed | (1.13) | (1.08) | |
| Return On Assets | (1.01) | (1.07) | |
| Return On Equity | (1.45) | (1.38) |
Things to note about Genelux Common performance evaluation
Checking the ongoing alerts about Genelux Common for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Genelux Common help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Genelux Common is way too risky over 90 days horizon | |
| Genelux Common appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 170 K. Net Loss for the year was (28.3 M) with profit before overhead, payroll, taxes, and interest of 11.07 M. | |
| Genelux Common generates negative cash flow from operations | |
| Genelux Common has a frail financial position based on the latest SEC disclosures | |
| About 16.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Frazier Life Sciences Appoints John Smither and Jim Williams as Senior Advisors |
- Analyzing Genelux Common's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Genelux Common's stock is overvalued or undervalued compared to its peers.
- Examining Genelux Common's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Genelux Common's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Genelux Common's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Genelux Common's stock. These opinions can provide insight into Genelux Common's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Genelux Stock Analysis
When running Genelux Common's price analysis, check to measure Genelux Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genelux Common is operating at the current time. Most of Genelux Common's value examination focuses on studying past and present price action to predict the probability of Genelux Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genelux Common's price. Additionally, you may evaluate how the addition of Genelux Common to your portfolios can decrease your overall portfolio volatility.